{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:41:34Z","timestamp":1789213294426,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018541","name":"Science Fund for Distinguished Young Scholars of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20211527"],"award-info":[{"award-number":["BK20211527"]}],"id":[{"id":"10.13039\/501100018541","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejmech.2025.118459","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T17:29:15Z","timestamp":1764955755000},"page":"118459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Benzoheterocyclic analogues of dotinurad as orally efficacious human urate transporter 1 inhibitors: Design, synthesis, structure-activity relationships, and pharmacokinetic studies"],"prefix":"10.1016","volume":"303","author":[{"given":"Linjian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaijun","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoshu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guowei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1898-3071","authenticated-orcid":false,"given":"Xiaojin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118459_bib1","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/art.41453","article-title":"Rising global burden of gout: time to act","volume":"72","author":"Danve","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.ejmech.2025.118459_bib2","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(21)00569-9","volume":"397","author":"Dalbeth","year":"2021","journal-title":"Gout. Lancet"},{"key":"10.1016\/j.ejmech.2025.118459_bib3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.maturitas.2018.10.012","article-title":"Gout - an update of aetiology, genetics, co-morbidities and management","volume":"118","author":"Robinson","year":"2018","journal-title":"Maturitas"},{"key":"10.1016\/j.ejmech.2025.118459_bib4","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41392-024-01916-y","article-title":"Hyperuricemia and its related diseases: mechanisms and advances in therapy","volume":"9","author":"Du","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.ejmech.2025.118459_bib5","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1080\/00325481.2016.1221732","article-title":"Overview of serum uric acid treatment targets in gout: why less than 6 mg\/dL?","volume":"128","author":"Ruoff","year":"2016","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.ejmech.2025.118459_bib6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1146\/annurev-immunol-051116-052406","article-title":"Purine release, metabolism, and signaling in the inflammatory response","volume":"37","author":"Linden","year":"2019","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2025.118459_bib7","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev-physiol-021113-170343","article-title":"The molecular physiology of uric acid homeostasis","volume":"77","author":"Mandal","year":"2015","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.ejmech.2025.118459_bib8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijcard.2015.08.109","article-title":"Regulation of uric acid metabolism and excretion","volume":"213","author":"Maiuolo","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ejmech.2025.118459_bib9","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1039\/D3MD00316G","article-title":"Past, present and future of xanthine oxidase inhibitors: design strategies, structural and pharmacological insights, patents and clinical trials","volume":"14","author":"Singh","year":"2023","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118459_bib10","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jare.2017.03.003","article-title":"Physiological functions and pathogenic potential of uric acid: a review","volume":"8","author":"El Ridi","year":"2017","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.ejmech.2025.118459_bib11","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1053\/j.ackd.2012.07.009","article-title":"Renal transport of uric acid: evolving concepts and uncertainties","volume":"19","author":"Bobulescu","year":"2012","journal-title":"Adv. Chronic Kidney Dis."},{"key":"10.1016\/j.ejmech.2025.118459_bib12","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/MNH.0000000000000427","article-title":"The systems biology of uric acid transporters: the role of remote sensing and signaling","volume":"27","author":"Nigam","year":"2018","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.ejmech.2025.118459_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050197","article-title":"SLC2A9 is a high-capacity urate transporter in humans","volume":"5","author":"Caulfield","year":"2008","journal-title":"PLoS Med."},{"key":"10.1016\/j.ejmech.2025.118459_bib14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/1759720X16646703","article-title":"Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications","volume":"8","author":"Sattui","year":"2016","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.ejmech.2025.118459_bib15","doi-asserted-by":"crossref","first-page":"14474","DOI":"10.1021\/acs.jmedchem.3c01710","article-title":"Agents for the treatment of gout: current advances and future perspectives","volume":"66","author":"Zeng","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118459_bib16","doi-asserted-by":"crossref","first-page":"19966","DOI":"10.1021\/acs.jmedchem.4c01260","article-title":"Recent progress and future perspectives on anti-hyperuricemic agents","volume":"67","author":"Sun","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118459_bib17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1124\/pr.58.1.6","article-title":"Therapeutic effects of xanthine oxidase inhibitors: Renaissance half a century after the discovery of allopurinol","volume":"58","author":"Pacher","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2025.118459_bib18","article-title":"Allopurinol for chronic gout","volume":"2014","author":"Seth","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejmech.2025.118459_bib19","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2125.2012.04207.x","article-title":"The pharmacokinetics of oxypurinol in people with gout","volume":"74","author":"Stocker","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"23","key":"10.1016\/j.ejmech.2025.118459_bib20","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker Michael","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118459_bib21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2007.08.036","article-title":"Allopurinol is the Most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel","volume":"58","author":"Halevy","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ejmech.2025.118459_bib22","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White William","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118459_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174291","article-title":"A brief review of urate transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia and gout: current therapeutic options and potential applications","volume":"907","author":"Song","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118459_bib24","doi-asserted-by":"crossref","first-page":"462","DOI":"10.2165\/00003088-199427060-00005","article-title":"Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs","volume":"27","author":"Brouwers","year":"1994","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2025.118459_bib25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s42358-019-0080-x","article-title":"Benzbromarone in the treatment of gout","volume":"59","author":"Azevedo","year":"2019","journal-title":"Adv. Rheumatol."},{"key":"10.1016\/j.ejmech.2025.118459_bib26","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.12998\/wjcc.v7.i13.1717","article-title":"Liver failure associated with benzbromarone: a case report and review of the literature","volume":"7","author":"Zhang","year":"2019","journal-title":"World J. Clin. Cases"},{"key":"10.1016\/j.ejmech.2025.118459_bib27","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0168-8278(94)80011-1","article-title":"Hepatic injury caused by benzbromarone","volume":"20","author":"van der Klauw","year":"1994","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2025.118459_bib28","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s40266-017-0461-y","article-title":"Lesinurad: a review in hyperuricaemia of gout","volume":"34","author":"Deeks","year":"2017","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ejmech.2025.118459_bib29","article-title":"Lesinurad, a selective URAT-1 inhibitor with a novel mechanism in combination with a xanthine oxidase inhibitor, for hyperuricemia associated with gout","author":"Huneycutt","year":"2017","journal-title":"J. Pharm. Pract."},{"key":"10.1016\/j.ejmech.2025.118459_bib30","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s40001-023-01208-1","article-title":"Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA)","volume":"28","author":"Tanaka","year":"2023","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.ejmech.2025.118459_bib31","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.tiv.2017.05.013","article-title":"The catechol-O-methyltransferase inhibitors tolcapone and entacapone uncouple and inhibit the mitochondrial respiratory chain in HepaRG cells","volume":"42","author":"Gr\u00fcnig","year":"2017","journal-title":"Toxicol. Vitro"},{"key":"10.1016\/j.ejmech.2025.118459_bib32","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1021\/acsmedchemlett.0c00176","article-title":"Discovery of dotinurad (FYU-981), a new phenol derivative with highly potent uric acid lowering activity","volume":"11","author":"Uda","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118459_bib33","doi-asserted-by":"crossref","first-page":"33421","DOI":"10.1021\/acsomega.0c05360","article-title":"Structural insights into the atomistic mechanisms of uric acid recognition and translocation of human urate anion transporter 1","volume":"5","author":"Zhao","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2025.118459_bib34","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41422-024-01023-1","article-title":"Transport mechanism and structural pharmacology of human urate transporter URAT1","volume":"34","author":"Dai","year":"2024","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2025.118459_bib35","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1124\/jpet.119.259341","article-title":"Pharmacological evaluation of dotinurad, a selective urate reabsorption inhibitor","volume":"371","author":"Taniguchi","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejmech.2025.118459_bib36","first-page":"16","article-title":"Biotransformation and uric acid lowering effect of benzbromarone in patients with liver cirrhosis - evidence for active benzbromarone metabolites?","volume":"1","author":"Walter-Sack","year":"1995","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.ejmech.2025.118459_bib37","first-page":"45","article-title":"Biliary excretion of benzbromarone and its hydroxilated main metabolites in humans","volume":"3","author":"Walter-Sack","year":"1998","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.ejmech.2025.118459_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114682","article-title":"Discovery of novel benzbromarone analogs with improved pharmacokinetics and benign toxicity profiles as antihyperuricemic agents","volume":"242","author":"Zhao","year":"2022","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425012243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425012243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:45:17Z","timestamp":1781325917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425012243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":38,"alternative-id":["S0223523425012243"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118459","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benzoheterocyclic analogues of dotinurad as orally efficacious human urate transporter 1 inhibitors: Design, synthesis, structure-activity relationships, and pharmacokinetic studies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118459","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118459"}}